Anika Therapeutics(US:ANIK)2022-08-06 07:09Financial Performance - Total revenue increased by 4% to $39.7 million[29] - OA Pain Management revenue increased by 6% to $25.7 million[29] - Joint Preservation and Restoration revenue increased by 2% to $12.1 million[29] - Non-Orthopedic revenue decreased by 6% to $1.8 million[29] - Gross margin was 63%, including $1.6 million of non-cash acquisition-related expenses; adjusted gross margin was 67%[29] - Net loss was ($2.8) million, or ($0.20) per share; adjusted net loss was ($1.6) million, or ($0.12) per share[29] - Adjusted EBITDA was $4.4 million[29] - Cash balance as of June 30, 2022, was $91.4 million[29] Business Highlights - Received 510(k) clearance for X-Twist™ fixation system, with limited market release planned for 2H 2022[5] - Continuing to ramp up Joint Preservation medical education activities, with 270 surgeons trained YTD[5] - Tactoset® received an ACE award for innovation at the American Orthopaedic Society for Sports Medicine (AOSSM) meeting[5] - Completed last patient follow-up in Cingal® pilot study, with data read-out planned for Fall 2022[5]